MedWatch

Large differences in transparency on collaborations between industry and physicians

In several EU countries there is a lack of transparency when it comes to financial transactions between the pharmaceutical industry and healthcare personnel, shows new study. In Denmark, special regulations have ensured full transparency on collaborations, but studies have shown that industry fees in Denmark influence physicians' prescription of medicine.

Foto: /ritzau/Martin Lehmann/Arkiv

There has to be transparency when it comes to physicians' and other healthcare professionals' collaborations with the pharmaceutical and medtech industry.

This has been the mantra for many years, however, many countries are not doing well when it comes to transparency and the extent of reporting as well as registration of relations between healthcare professionals and the industry, according to a new study published in the International Journal of Health Policy and Management (IJHPM).

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Headhunter: Afgående Leo-boss var et flop

Det var et fejlskud at ansætte Catherine Mazzacco som adm. direktør for Leo Pharma, vurderer headhunter, der ser afgangen som et naturligt skridt forud for børsnoteringen af Leo Pharma. Til at styre den proces i mål vil bestyrelsen efter alt at dømme skulle til udlandet for at finde den rette profil, lyder det videre.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier